降钙素原作为心脏骤停后患者预后标志物的系统评价与荟萃分析
该系统评价与荟萃分析检索了MEDLINE、EMBASE和Cochrane Library(检索日期2019年1月8日),纳入10项研究共1065例院外心脏骤停后恢复自主循环并测量降钙素原的患者。入院0–24小时降钙素原升高与院内死亡相关(SMD 0.64,95%CI 0.33–0.95,I²=26%);0–48小时降钙素原升高也与不良神经预后相关(0–24小时SMD 0.61,95%CI 0.44–0.79,I²=0%;24–48小时SMD 0.58,95%CI 0.35–0.82,I²=0%),并在1–6个月随访中持续相关(24–48小时SMD 0.62,95%CI 0.36–0.88,I²=0%)。作者结论认为心脏骤停后综合征0–48小时内降钙素原升高与不良预后相关。
要点
- 院外心脏骤停恢复自主循环患者入院0–24小时降钙素原升高与院内死亡相关(SMD 0.64,95%CI 0.33–0.95,I²=26%)。
- 0–24小时降钙素原升高与不良神经预后相关(SMD 0.61,95%CI 0.44–0.79,I²=0%)。
- 24–48小时降钙素原升高与不良神经预后相关(SMD 0.58,95%CI 0.35–0.82,I²=0%)。
- 24–48小时降钙素原升高与1–6个月不良神经预后相关(SMD 0.62,95%CI 0.36–0.88,I²=0%)。
- 作者认为心脏骤停后综合征0–48小时内降钙素原升高与不良预后相关。
适用人群与场景
- 院外心脏骤停后恢复自主循环(ROSC)的患者,在出院时及出院后评估降钙素原水平与预后。
研究设计与关键结果
- 系统评价与荟萃分析,最终纳入10项研究共1065例患者。
- 入院0–24小时降钙素原升高与院内死亡相关:SMD 0.64(95%CI 0.33–0.95),I²=26%。
- 0–24小时降钙素原升高与不良神经预后相关:SMD 0.61(95%CI 0.44–0.79),I²=0%。
- 24–48小时降钙素原升高与不良神经预后相关:SMD 0.58(95%CI 0.35–0.82),I²=0%。
- 24–48小时降钙素原升高与1–6个月不良神经预后相关:SMD 0.62(95%CI 0.36–0.88),I²=0%。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析。
- 采用Quality in Prognosis Studies工具评估纳入研究的偏倚风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为心脏骤停后综合征0–48小时内降钙素原升高与不良预后相关。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: This study aimed to seek evidence for the usefulness of the procalcitonin as a prognostic blood biomarker for outcomes in post-cardiac arrest patients.
METHODS: We systematically searched MEDLINE, EMBASE, and the Cochrane Library (search date: 8 January, 2019). Studies on patients who experienced return of spontaneous circulation, who had out of hospital cardiac arrest and had their level of procalcitonin measured and outcomes assessed at and after hospital discharge, were included. We additionally performed subgroup analyses for confounding factors affecting patients' outcomes. To assess the risk of bias of each included study, the Quality in Prognosis Studies tool was used.
RESULTS: A total of 1065 patients from 10 studies were finally included. Elevated procalcitonin level during hospital admission (at 0-24 h) was associated with in-hospital mortality (standardized mean difference (SMD) 0.64, 95% confidence interval (CI) 0.33-0.95, I2 = 26%). The elevation of procalcitonin level (at 0-48 h) was also associated with poor neurologic outcomes (at 0-24 h, SMD 0.61; 95% CI 0.44-0.79, I2 = 0%; at 24-48 h, SMD 0.58, 95% CI 0.35-0.82, I2 = 0%) as well as at 1-6 months (at 24-48 h, SMD 0.62; 95% CI 0.36-0.88, I2 = 0%).
CONCLUSIONS: Overall, the findings suggested that an elevated procalcitonin level measured at 0-48 h of post-cardiac arrest syndrome was associated with poor outcomes.
参考来源
- Shin H, Kim JG, Kim W, et al. Procalcitonin as a prognostic marker for outcomes in post-cardiac arrest patients: A systematic review and meta-analysis. Resuscitation. 2019. PMID: 30872069. doi:10.1016/j.resuscitation.2019.02.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。